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Abstract
Endothelial dysfunction is more prevalent in African Americans (AA) compared to whites. We 
hypothesized that nebivolol, a selective β-1 antagonist that stimulates NO, will improve 
endothelial function in AA with hypertension when compared to metoprolol. In a double-blind, 
randomized, cross-over study, 19 AA hypertensive subjects were randomized to a 12-week 
treatment period with either nebivolol 10mg or metoprolol succinate 100mg daily. Forearm blood 
flow (FBF) was measured using plethysmography at rest and after intra-arterial infusion of 
acetylcholine, and sodium nitroprusside to estimate endothelium-dependent and independent 
vasodilation, respectively. Physiologic vasodilation was assessed during hand-grip exercise. 
Measurements were repeated after NO blockade with L-NG-monomethylarginine (L-NMMA), and 
after inhibition of endothelium-derived hyperpolarizing factor (EDHF) with tetraethylammonium 
chloride (TEA). NO blockade with L-NMMA produced a trend toward greater vasoconstriction 
during nebivolol compared to metoprolol treatment period (21% vs 12% reduction in FBF, 
p=0.06, respectively). This difference was more significant after combined administration of L-
NMMA and TEA (p<0.001). Similarly, there was a contribution of NO to exercise-induced 
vasodilation during nebivolol but not during metoprolol treatment. There were significantly 
greater contributions of NO and EDHF to resting vasodilator tone and of NO to exercise-induced 
vasodilation with nebivolol compared to metoprolol in AA with hypertension.
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INTRODUCTION
Endothelial dysfunction precipitated by loss of nitric oxide (NO) bioavailability is associated 
with exposure to cardiovascular risk factors. African Americans (AA) shoulder a higher 
burden of hypertension and its associated target organ damage including nephropathy, 
stroke, myocardial infarction and cardiovascular mortality.1 In comparison to their white 
counterparts, AAs have decreased NO bioavailability and worse endothelial function that 
has been attributed to both decreased production and increased degradation of NO.2–5
Nebivolol is a third-generation, β1-adrenergic receptor antagonist with vasodilatory 
properties that appear to be independent of β1-receptor antagonism and related to β3-receptor 
agonist effects.6–8 It stimulates nitric oxide release through β3-receptor and ATP-dependent, 
P2Y-receptor activation. 6,9–13 In hypertensive patients, vasodilation with nebivolol is 
evident after a single dose and persists after chronic administration.14,15 Furthermore, 
nebivolol increased endothelium-dependent vasodilation with acetylcholine when compared 
to atenolol in whites with hypertension.16
Endothelium-dependent vasodilation in response to agonists such as acetylcholine and 
bradykinin is due to the release of several factors including NO, endothelium-derived 
hyperpolarization factor (EDHF), prostaglandins, and others.17 EDHF release may 
compensate for reduced NO bioavailability in certain disease states and contributes to 
physiologic vasodilation due to exercise.17–20 Although there may be several EDHFs, they 
all relax vascular smooth muscle via activation of calcium-dependent potassium channels 
that can be inhibited with tetraethylammonium chloride (TEA).20 Using these antagonists, 
we and others have shown that EDHF contributes to resting vasodilator tone and to 
bradykinin-mediated vasodilation in healthy subjects.17 Furthermore, we found that NO but 
not EDHF activity is reduced in the forearm vasculature of AA compared to whites.4
Because of the reduction in NO bioavailability in the vasculature of AA, we sought to 
determine whether nebivolol, compared to metoprolol, can selectively improve endothelial 
function by modulating NO and EDHF activities in AAs with hypertension. We tested the 
hypothesis that nebivolol, by increasing NO bioavailability, would improve endothelial 
function compared to matched hypotensive doses of sustained release metoprolol in AA 
with hypertension.
METHODS
Study design
In a randomized, double-blind, crossover study, subjects with resting blood pressure (BP) 
>135/85 (GE Dynamap) were randomized to receive either nebivolol or metoprolol 
succinate in addition to their current regimen of anti-hypertensive medications (Figure 1A). 
Subjects with hypertension and BP<135/85 at randomization had their regimen altered by 
decreasing the dose of concomitant medications. The study drug was initiated as either 
nebivolol 5mg or metoprolol succinate 50mg daily. After 2 weeks, the dose of the study 
drug was increased to either nebivolol 10mg or metoprolol 100mg if BP remained >125/80. 
Subjects continued the highest titrated dose of study drug for an additional 10 weeks prior to 
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performance of vascular studies. At the end of the first treatment phase, subjects crossed 
over into the alternate treatment arm. BP was measured at each visit after a 10-minute rest 
period using a mean of 3 measurements taken 5 minutes apart. The study was reviewed and 
approved by the Emory University Institutional Review Board. All subjects provided written 
informed consent.
Subjects
Self-identified AA subjects aged 22–80 years old with a history of essential hypertension 
were recruited. Exclusion criteria included initiation or change in statin or anti-hypertensive 
therapy, occurrence of stroke or acute coronary syndrome within 2 months prior to 
randomization, presence of chronic stable angina, current neoplasm, symptoms of heart 
failure, aortic stenosis, chronic kidney or liver diseases (creatinine >2.5mg/dL, liver 
enzymes > twice upper limit of normal), and premenopausal females with the potential for 
pregnancy. Subjects with contra-indications to beta blockade (i.e. second or third degree AV 
block, bradycardia, severe reactive airways disease) were also excluded. Concurrent therapy 
with angiotensin antagonists (ACE inhibitors or ARBs) was not permitted. Allowable 
concurrent anti-hypertensive therapy included thiazide diuretics, calcium channel 
antagonists, clonidine, and vasodilators. Subjects on beta-adrenergic blockers had their drug 
changed to the study drug at time of enrollment. Subjects with co-morbid cardiovascular risk 
factors including hyperlipidemia, diabetes and smoking were included as long as there was 
no recent or planned change in therapy within 2 months of randomization and during the 
course of the study.
Materials
L-NMMA: NG-mono- methyl-L-arginine (L-NMMA; Bachem, Laufelfingen, Switzerland) is 
an analogue of L-arginine which competitively and irreversibly inhibits the generation of 
NO from arginine by nitric oxide synthases (NOS1, NOS2 and NOS3). Given at 8 μmol/min 
it attenuates agonist- and exercise-stimulated FBF, respectively.21,22 TEA: 
Tetraethylammonium (Sigma Aldrich) is a quaternary ammonium compound which 
selectively blocks voltage-sensitive potassium channels. When given at 1 mg/min, TEA is 
known to selectively inhibit K+Ca channels and inhibits bradykinin-mediated 
vasodilation.23–25 Sodium nitroprusside is an endothelium-independent vasodilator that acts 
as a direct nitric oxide donor.26 Its infusion serves to detect alterations in vascular smooth 
muscle sensitivity to nitric oxide. Acetylcholine (Novartis, East Hanover, NJ) is an 
endothelium-dependent vasodilator that stimulates nitric oxide release from endothelial 
cells.27
Measurement of forearm blood flow
Subjects refrained from exercise, alcohol, tobacco and caffeine for at least 24 hours before 
the study admission. After an overnight fast in a quiet temperature-controlled (22 to 24°C) 
room, subjects received 975mg of aspirin to inhibit prostacyclin synthesis at least 1 hour 
prior to the study.28 A 20-gauge catheter (Teleflex Inc, Research Triangle Park, NC) was 
inserted in the brachial artery of the non-dominant arm under direct ultrasound guidance for 
intra-arterial drug infusions, pressure monitoring, and blood sampling. Simultaneous 
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forearm blood flow (FBF) measurements were obtained in both arms using a dual-channel 
venous occlusion strain gauge plethysmograph (model EC6, DE Hokanson, Bellevue, WA) 
as described previously.17,21 Flow measurements were recorded for approximately 7 
seconds, every 15 seconds up to eight times and a mean FBF value in mL·min−1·100 mL−1 
was computed. Forearm vascular resistance (FVR) was calculated as the mean arterial 
pressure ÷ FBF and expressed as mmHg per mL·min−1·100 mL−1.
All agents were administered intra-arterially. Resting FBF measurements were made after 
15 minutes of normal saline infusion (1.5ml/min) and repeated during intra-arterial infusion 
of the acetylcholine at 7.5, 15 and 30 μg/min for 5 minutes each. Physiologic forearm 
vasodilation was investigated using intermittent handgrip exercise where the evaluated 
forearm was exercised by squeezing an inflated pneumatic bag as previously described.21,29 
Exercise was performed at 15%, 30%, and 45% of the subject’s maximum voluntary grip 
strength. Each contraction lasted for 5 seconds followed by relaxation for 10 seconds and 
was repeated for 5 minutes at each workload. FBF was measured in the final 2 minutes of 
each dose/exercise workload.
After recovery, the acetylcholine and exercise protocol was repeated during inhibition of NO 
synthesis with the concomitant infusion of L-NMMA at 8 μmol/min during acetylcholine 
infusion and 16μmol/min during exercise. After recovery, while continuing L-NMMA, TEA 
was infused intra-arterially at 1 mg/min and acetylcholine and exercise protocols were 
repeated. Thus, we measured resting vasomotor tone, acetylcholine- and exercise-mediated 
vasodilation under control conditions, during NO blockade, and during combined NO and 
EDHF blockade allowing quantification of NO- and EDHF-dependent vasodilation. Finally, 
sodium nitroprusside was infused intra-arterially at 1.6 and 3.2 μg/min for 5 minutes each 
with FBF and FVR measured with each dose. L-NMMA and TEA have both been shown to 
not alter vasodilator responses to nitroprusside (Figure 1B).17
Analysis of inorganic nitrite and nitrate levels
Plasma nitrite and nitrate were measured from blood samples collected prior to FBF studies 
into distilled water-rinsed centrifuge tubes containing 100 mL of 100 mmol/L N-
ethylmaleimide and 5 mL of 0.5 mmol/L EDTA. Extracted plasma was flash frozen and 
stored at −80°C and subsequently analyzed for nitrite and nitrate levels by ion 
chromatography (ENO20, Eicom USA, San Diego, CA) as previously described.30
Statistical Analysis
Descriptive subject characteristics were reported as means, standard deviations (SD), 
standard errors (in figures), and percentages. A paired student’s t-test was used to compare 
BP between treatment phases. Analysis of FBF and FVR measurements was performed 
using linear mixed effects modeling with repeated measures, after log-transformation of the 
non-normal and positively skewed variables. An unstructured covariance form was assumed 
for the repeated measures. In the model, treatment period (metoprolol or nebivolol) and 
inhibitor (L-NMMA, TEA, L-NMMA and TEA) were added as fixed effects, and subject ID 
as a random effect. Based on previous studies, with a sample size of 20 we should detect a 
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10% or greater change between the two drugs in FBF with L-NMMA or TEA with α=0.05 
and power=0.8. 15,16
RESULTS
Subjects
Of the 19 subjects (13 men and 6 women) recruited, 74% were on one or more anti-
hypertensive medications, most commonly diuretics and calcium channel antagonists (Table 
1). Fourteen subjects (74%) reached the target doses of nebivolol 10mg and metoprolol 
100mg. Of the 5 subjects who did not require up-titration, 2 were controlled on nebivolol 
5mg and metoprolol 50mg, 1 required nebivolol 5mg and metoprolol 100mg, and 2 required 
nebivolol 10mg and metoprolol 50mg.
Resting forearm vascular tone
The heart rate and blood pressure was similar during both nebivolol and metoprolol 
treatment periods (Table 1). Resting vasodilator tone was also similar with the two study 
agents; FBF 2.8±1.3 and 2.9±1.2 mL·min−1·100 mL−1, p=0.6 and FVR 40.8±17 and 
37.5±12 mmHg/mL·min−1·100 mL−1, p=0.8 with nebivolol and metoprolol, respectively 
(Figure 2).
NO blockade with L-NMMA reduced resting FBF by 21% with nebivolol and 12% with 
metoprolol (both p<0.001 compared to baseline, and p=0.06 between groups for comparison 
of absolute values, and p=0.053 for comparison of % change in FBF). Similarly, FVR 
increased by 26% with nebivolol and 18% with metoprolol (both p<0.001 compared to 
baseline, p=0.1 between groups for comparison of absolute values, and p=0.1 for 
comparison of % change in FVR) (Figure 2). Addition of, K+Ca channel blockade with TEA 
to L-NMMA resulted in further significant reduction in FBF and an increase in FVR with 
nebivolol but not metoprolol (p<0.001) (Figure 2). Thus, there was a greater contribution of 
NO and EDHF combined to resting blood flow during therapy with nebivolol compared to 
metoprolol with NO accounting for the majority of the difference.
Acetylcholine-mediated vasodilation
Acetylcholine produced a similar dose-dependent increase in FBF and a concurrent decrease 
in FVR with both nebivolol and metoprolol (both p=0.6) (Figure 3). L-NMMA co-infusion 
attenuated acetylcholine-mediated vasodilation during treatment with both drugs, resulting 
in a 23.1±27.3%, p=<0.001 and a 14.8±35.5%, p=0.002 decrease in FBF with nebivolol and 
metoprolol, respectively (Figure 4). The difference between the groups did not reach 
statistical significance (p=0.4). Addition of TEA to L-NMMA did not further impact either 
the FBF or FVR during either the nebivolol or metoprolol treatment periods, indicating lack 
of contribution of EDHF to acetylcholine-mediated vasodilation with either drug (Figure 4).
Exercise-induced vasodilation
Graded exercise produced progressive forearm vasodilation that was similar during 
treatment with nebivolol and metoprolol (p=0.3 and p=0.4, respectively) (Figure 3C, D). 
With nebivolol however, NO antagonism with L-NMMA resulted in a significant decrease 
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in FBF (p=0.001) and increase in FVR (p<0.001) (Figure 5). There was no significant 
change in FBF or FVR with L-NMMA during the metoprolol treatment period (Figure 5). 
This suggests a significant contribution of NO to exercise-mediated vasodilation with 
nebivolol, but not with metoprolol treatment. Combined administration of L-NMMA and 
TEA produced no further reduction in FBF or increase in FVR during either the metoprolol 
or nebivolol treatment periods, indicating lack of contribution of EDHF to exercise-
mediated vasodilation with either beta-antagonist (Figure 5).
Sodium nitroprusside-induced vasodilation
Sodium nitroprusside infusion produced similar vasodilation during treatment with nebivolol 
and metoprolol (Figure 3E and 3F) indicating no differences in endothelium-independent 
vasodilation with these agents.
Plasma nitrite and nitrate levels
Plasma nitrite and nitrate levels were similar during treatment with nebivolol (0.17±0.1 and 
9.3±3.5 μmol/L) and metoprolol (0.17±0.1 and 8.7±4.1 μmol/L, p= 0.7 and 0.5, 
respectively).
DISCUSSION
Compared to whites, both healthy and hypertensive AA have diminished basal NO activity 
and reduced endothelium-dependent and -independent vasodilation. 4,31–36 In this study, we 
found evidence for NO bioavailability at rest during treatment with both nebivolol and 
metoprolol succinate in hypertensive AA subjects, with a clear trend for a greater 
contribution of NO during nebivolol therapy. Moreover, after combined blockade of NO and 
EDHF, there was a significantly greater vasoconstriction during nebivolol compared 
metoprolol therapy, suggesting greater contribution of both NO and EDHF combined to 
resting vasomotor tone during nebivolol treatment. Moreover, the contribution of NO to 
exercise-induced vasodilation was greater during treatment with nebivolol compared to 
metoprolol succinate. This is the first study to explore the role of nebivolol compared to 
metoprolol in AA hypertensives who have profound abnormalities in NO bioavailability. 
Specifically, we demonstrate a greater contribution of endothelium-derived vasodilators to 
resting FBF and greater contribution of NO to vasodilation during exercise with nebivolol 
compared to metoprolol. We found no differences in acetylcholine-mediated vasodilation 
between these agents, a finding that is different from that reported in white hypertensive 
subjects who received either nebivolol or atenolol.16
We have previously shown that there is no contribution of NO at rest and after acetylcholine 
in hypertensive subjects (no effect of L-NMMA).37–43 Here we demonstrate that there is 
some contribution of NO after AA hypertensives are treated with beta adrenergic blockade, 
and further show that this is higher with nebivolol at rest compared to metoprolol. In healthy 
subjects, L-NMMA reduces resting flow by 30 to 40%. After beta blockade, we show that 
even in hypertensives, it is restored to approximately half of what it is in healthy subjects.
Exercise-induced vasodilation is a complex process involving multiple vasodilator 
mechanisms including a modest contribution of NO and various putative EDHFs.4,21,44,45 
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We have previously demonstrated that both NO and EDHF contribute individually and in 
concert to exercise-induced microvascular vasodilation in the healthy human forearm 
circulation. Nebivolol, but not metoprolol restored functional sympatholysis that is impaired 
in working muscle in hypertensive patients.46 In this study, while there was no difference in 
the magnitude of vasodilation during exercise between treatments, we observed a significant 
contribution of NO to exercise-induced vasodilation during the nebivolol but not the 
metoprolol treatment period. This suggests that nebivolol restores contribution of NO to 
exercise-induced vasodilation in AA with hypertension. Interestingly, neither drug increased 
the contribution of EDHF to exercise-induced vasodilation.
In previous studies in hypertensive subjects from both ethnicities, we and others found that 
acetylcholine-mediated NO release was lower compared to normotensive controls.4,34–36 In 
fact, L-NMMA did not inhibit acetylcholine responses in untreated hypertensive subjects. 
Herein, we show significant NO release in response to acetylcholine during treatment with 
both beta-receptor antagonists. In a previous study of European subjects with hypertension, 
increased acetylcholine-mediated NO activity was reported with nebivolol but not after 
atenolol.16 Improved NO activity with endothelium-dependent vasodilators long-acting 
metoprolol may thus account for the benefits of this preparation compared to atenolol.47
Greater NO activity was found in internal mammary artery and vein specimens from 
subjects pre-treated with nebivolol compared to metoprolol.48 In subjects with coronary 
artery disease or hypertension, nebivolol, but not atenolol improved flow-mediated dilation 
(FMD) and lowered asymmetric dimethylarginine (ADMA) levels, a naturally occurring 
amino acid that inhibits eNOS. 15,49 Finally, in AA with stage 1 hypertension, nebivolol 
monotherapy increased FMD and improved arterial wave reflections compared to untreated 
state.50 In contrast, no differences between metoprolol succinate and nebivolol were 
observed in aortic compliance indices in a largely AA population of diabetics.51
Moreover, these experiments were performed in the setting of prostacyclin inhibition. The 
contribution of the prostacyclin pathway was thus not investigated in this study and may 
potentially be also affected by beta-blockade. Whether other endogenous vasodilators such 
as prostacyclin, adenosine, carbon monoxide and others are affected differentially by 
nebivolol versus other beta-blockers needs to be studied.
Strengths and limitations
Strengths of our study include the blinded crossover design and investigation in AA 
hypertensive subjects who are at particularly high cardiovascular risk and have profound NO 
abnormalities. We have also examined the contribution of both NO and EDHF to resting, 
acetylcholine-mediated and exercise-induced vasodilation. Limitations include the small 
sample size, the heterogeneity of the population, which was largely driven by the 
requirement of repeated intra-arterial cannulation. The lack of placebo treatment phase 
would have allowed comparison of either agent with no therapy, however this was precluded 
by potential hazards of performing three invasive studies in the same subject. This study also 
did not include other beta-receptor antagonist comparators such as atenolol. In addition, the 
interaction of concomitant medications such as thiazides or diuretics with the study drugs on 
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NO bioavailability, while largely controlled by the cross-over design and stable dosing, 
could not be examined.
CONCLUSIONS
In conclusion, there was significant contribution of NO and EDHF to resting vasodilator 
tone and a significant contribution of NO to exercise-induced vasodilation with nebivolol 
compared to an equipotent dose of metoprolol.succinate. These findings demonstrate 
selective effects of nebivolol on NO activity in AA with hypertension and provide 
mechanistic insights into endothelial dysfunction in this at-risk group. Further study is 
needed to establish if these observations translate into clinically meaningful outcomes.
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Figure 1. 
Study design (A) and protocol (B)
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Figure 2. 
Contribution of nitric oxide and K+Ca channel activation to resting forearm blood flow and 
vascular resistance during treatment with nebivolol (A and C) and metoprolol (B and D). 
Responses to infusion of L-NMMA and combined infusions of L-NMMA and TEA are 
shown. P values for effect of L-NMMA and TEA on FBF and FVR. Data presented as mean
±SEM.
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Figure 3. 
Endothelium-dependent FBF (A) and FVR (B) changes with acetylcholine, endothelium-
independent changes in FBF (C) and FVR (D) with sodium nitroprusside, and forearm 
exercise induced changes in FBF (E) and FVR (F) during treatment with nebivolol and 
metoprolol. P values are for treatment effect of nebivolol/metoprolol by mixed model. Data 
presented as mean±SEM.
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Figure 4. 
Contribution of nitric oxide and K+Ca channel activation to acetylcholine-mediated 
vasodilation during treatment with nebivolol (A and C) and metoprolol (B and D). FBF and 
FVR responses to increasing doses of acetylcholine alone after initial infusion of L-NMMA, 
and combined blockade with L-NMMA and TEA are shown. P values are for effect of L-
NMMA and TEA by mixed model. *p denotes p-value for comparison of L-NMMA and 
control, non-starred p reflects p-value for comparison of L-NMMA and L-NMMA+TEA. 
Data presented as mean±SEM.
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Figure 5. 
Contribution of nitric oxide and K+Ca channel activation to forearm exercise mediated 
vasodilation during treatment with nebivolol (A and C) and metoprolol (B and D). FBF and 
FVR responses to increasing doses of acetylcholine alone, after initial infusion of L-
NMMA, and combined blockade with L-NMMA and TEA are shown. P values are for effect 
of L-NMMA and TEA by mixed model. *p denotes p-value for comparison of L-NMMA 
and control, non-starred p reflects p-value for comparison of L-NMMA and L-NMMA
+TEA. Data presented as mean±SEM.
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Table 1
Characteristics of Study Subjects
Hypertensive African-Americans (n=19)
Age, years 51±8.6
Male/Female 13/6
Diabetes mellitus, n (%) 1(5.1%)
Smoker, n (%) 7 (36.8%)
Hypercholesterolemia, n (%) 6 (31.5%)
Family History of CAD, n (%) 6 (31.5%)
Statin Therapy, n (%) 4 (21%)
Weight, kg 96.5±22.3
Body mass index, kg/m2 32.5±7.4
Concurrent anti-hypertensive drugs
 Diuretic (thiazide) 8 (42.1%)
 Calcium Channel Antagonist 5 (26.3%)
On-Treatment Hemodynamic Data Nebivolol Metoprolol succinate p-value
Systolic Blood Pressure, mmHg 135±15 134±15 0.8
Diastolic blood pressure, mmHg 81±14 81±21 0.8
Resting heart rate, bpm 63±8 64±9 0.8
*
Data are Mean ±SD
J Clin Hypertens (Greenwich). Author manuscript; available in PMC 2017 March 01.
